You can also find #ASCO13 PI3K abstracts here.
PHOSPHOINOSITIDE-3-KINASE-‐δ,-‐γ,
IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL
LYMPHOMA
B. Kahl, Madison, WI (USA)
145 PRELIMINARY SAFETY AND EFFICACY OF IPI-145, A POTENT INHIBITOR OF
PHOSPHOINOSITIDE-3-KINASE-‐δ,-‐γ,
IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL
I.W. Flinn, Nashville, TN (USA)
064bis INTERIM RESULTS FROM A PHASE 2 STUDY OF PI3K?? INHIBITOR IDELALISIB IN PATIENTS WITH
RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (iNHL) REFRACTORY TO BOTH RITUXIMAB AND
AN ALKYLATING AGENT
G. Salles, Pierre Bénite, France
068 COMBINATIONS OF THE PI3Kδ INHIBITOR IDELALISIB (GS-1101) WITH RITUXIMAB AND/OR
BENDAMUSTINE ARE TOLERABLE AND HIGHLY ACTIVE IN PATIENTS WITH PREVIOUSLY
TREATED, INDOLENT NON-HODGKIN LYMPHOMA (INHL): UPDATED RESULTS FROM A PHASE I
STUDY
J.P. Leonard, New York, NY (USA)
069 PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB,
CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE
(R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)
A. Younes, New York, NY (USA)
038 NOVEL PI3K-δ INHIBITORS DEMONSTRATED MARKED CYTOTOXICITY IN T CELL
LYMPHOMA MODELS AND WERE SYNERGISTIC WITH A NOVEL ANTI-CD20 MAB,
UBLITUXIMAB, IN LYMPHOMA MODELS
C. Deng, New York NY (USA)
110 A HIGH PIK3CA/PIK3CD MRNA RATIO IN MANTLE CELL LYMPHOMA CAN PREDICT
RESISTANCE TO PI3Kδ INHIBITION AND IS MORE COMMON WITH MULTIPLE RELAPSE
S. Iyengar, London (UK)
139 PILOT PHASE 2 STUDY OF IDELALISIB, A SELECTIVE INHIBITOR OF PI3Kδ, IN
PATIENTS WITH HEAVILY PRETREATED HODGKIN LYMPHOMA (HL)
A. Younes, New York, NY (USA)
067 A PROSPECTIVE, MULTICENTER, PHASE II STUDY OF THE BRUTON’S TYROSINE
KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH RELAPSED AND REFRACTORY
WALDENSTROM’S MACROGLOBULINEMIA
S.P. Treon, Boston, MA (USA)